Dongdong Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dongdong Zhang has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
Youhong Dong
Department of Oncology, Xiangyang No. 1 People’s Hospital, Hubei University of Medicine
10 shared publications- Youhong Dong
Department of Oncology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei 441000, P.R. China
7 shared publications Han Yu
Department of Pathology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei 441000, P.R. China
5 shared publicationsHong Li
Department of Internal Medicine II, University Hospital Bonn, Rheinische Friedrich-Wilhelms University of Bonn Venusberg-Campus 1
5 shared publicationsShiyue Liu
Department of Oncology, Xiangyang No.1 Peoplès Hospital, Hubei Univeristy of Medicine
5 shared publicationsYuejian Zhuo
Department of Oncology, Xiangyang No. 1 People’s Hospital, Hubei University of Medicine, Xiangyang, 441000, People’s Republic of China
5 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1910294
Case Report: Diagnostic dilemma: rebound thymic hyperplasia mimicking mediastinal relapse following chemoimmunotherapy in pediatric jejunal Burkitt lymphoma
Background: Pediatric sporadic Burkitt lymphoma (BL) typically presents with gastrointestinal involvement; primary mediastinal disease is exceedingly rare. Rebound thymic hyperplasia (RTH) is a benign regenerative process following chemotherapy that can radiologically mimic mediastinal relapse, creating significant diagnostic challenges in post-treatment surveillance. Case presentation: An 8-year-old male was diagnosed with St. Jude stage III Burkitt lymphoma (BL) following the emergency resection of a jejunal mass. After receiving risk-adapted chemoimmunotherapy, he achieved a complete metabolic response. Three months post-treatment, routine surveillance computed tomography (CT) revealed a new anterior mediastinal soft tissue mass, magnetic resonance imaging (MRI) revealing T2 hyperintensity in the anterior mediastinal lesion without restricted diffusion, while subsequent PET/CT demonstrated mildly increased FDG uptake, raising immediate clinical concern for disease relapse. To rule out malignancy, a CT-guided percutaneous biopsy was performed. Histopathological analysis revealed normal thymic microarchitecture containing Hassall’s corpuscles. The final imaging and pathological findings supported a diagnosis of chemotherapy-induced rebound thymic hyperplasia (RTH). Conclusion: Cytotoxic therapy induces profound thymic involution, often followed by striking regenerative expansion upon treatment cessation. Recognizing RTH is paramount to avoid misdiagnosing neoplastic recurrence and administering unwarranted therapies. This case highlights need to integrate advanced imaging and tissue biopsy when evaluating new mediastinal opacities in pediatric lymphoma survivors.
- 15 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1910294
Open AccessCase Report: Diagnostic dilemma: rebound thymic hyperplasia mimicking mediastinal relapse following chemoimmunotherapy in pediatric jejunal Burkitt lymphoma
Background: Pediatric sporadic Burkitt lymphoma (BL) typically presents with gastrointestinal involvement; primary mediastinal disease is exceedingly rare. Rebound thymic hyperplasia (RTH) is a benign regenerative process following chemotherapy that can radiologically mimic mediastinal relapse, creating significant diagnostic challenges in post-treatment surveillance. Case presentation: An 8-year-old male was diagnosed with St. Jude stage III Burkitt lymphoma (BL) following the emergency resection of a jejunal mass. After receiving risk-adapted chemoimmunotherapy, he achieved a complete metabolic response. Three months post-treatment, routine surveillance computed tomography (CT) revealed a new anterior mediastinal soft tissue mass, magnetic resonance imaging (MRI) revealing T2 hyperintensity in the anterior mediastinal lesion without restricted diffusion, while subsequent PET/CT demonstrated mildly increased FDG uptake, raising immediate clinical concern for disease relapse. To rule out malignancy, a CT-guided percutaneous biopsy was performed. Histopathological analysis revealed normal thymic microarchitecture containing Hassall’s corpuscles. The final imaging and pathological findings supported a diagnosis of chemotherapy-induced rebound thymic hyperplasia (RTH). Conclusion: Cytotoxic therapy induces profound thymic involution, often followed by striking regenerative expansion upon treatment cessation. Recognizing RTH is paramount to avoid misdiagnosing neoplastic recurrence and administering unwarranted therapies. This case highlights need to integrate advanced imaging and tissue biopsy when evaluating new mediastinal opacities in pediatric lymphoma survivors.
- Open Access
The Novel Organic Arsenical PZ2 Exhibits Potent Anti-T-ALL Activity via ROS-Dependent Apoptosis and GABARAPL1-Induced Autophagic Cell Death
Objective: T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive hematological malignancy with poor overall prognosis. This study systematically evaluates the anti-leukemic therapeutic potential and underlying redox-driven mechanisms of PZ2, a novel organic arsenic compound, in T-ALL. Methods: The cytotoxicity of PZ2 against T-ALL cell lines and normal cells was assessed to determine its therapeutic window. RNA-seq was utilized to map transcriptomic alterations. Intracellular redox homeostasis, mitochondrial membrane potential (MMP), cell cycle, and apoptosis were evaluated using flow cytometry and fluorescence microscopy. Ultrastructural changes and key protein expressions were analyzed via TEM, RT-qPCR, and immunoblotting. In vivo efficacy was validated using a T-ALL cell-line-derived xenograft (CDX) mouse model. Results: PZ2 exhibited superior cytotoxicity and an improved safety profile compared to inorganic arsenic trioxide (ATO). Transcriptomic data indicated strong enrichment in apoptosis and autophagy–lysosome pathways. PZ2 induced profound mitochondrial oxidative stress, leading to ROS accumulation, MMP loss, and subsequent activation of caspase-dependent apoptosis—effects that were completely rescued by ROS scavengers. Furthermore, PZ2 triggered G2/M phase arrest and activated autophagic flux (upregulated GABARAPL1 and LC3-II, degraded p62). Notably, pharmacological inhibition of autophagy rescued PZ2-induced apoptosis, revealing a pro-death autophagic mechanism. In vivo, PZ2 significantly suppressed tumor growth and prolonged survival without overt systemic toxicity. Conclusions: PZ2 exhibits potent anti-T-ALL activity that may involve a dual mechanism: ROS-dependent mitochondrial apoptosis and pro-death autophagy potentially associated with GABARAPL1. This novel organic arsenical may represent a promising and potentially safer alternative for leukemia therapy, and these findings suggest a potential interplay between oxidative stress and autophagic cell death.
Open AccessThe Novel Organic Arsenical PZ2 Exhibits Potent Anti-T-ALL Activity via ROS-Dependent Apoptosis and GABARAPL1-Induced Autophagic Cell Death
Objective: T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive hematological malignancy with poor overall prognosis. This study systematically evaluates the anti-leukemic therapeutic potential and underlying redox-driven mechanisms of PZ2, a novel organic arsenic compound, in T-ALL. Methods: The cytotoxicity of PZ2 against T-ALL cell lines and normal cells was assessed to determine its therapeutic window. RNA-seq was utilized to map transcriptomic alterations. Intracellular redox homeostasis, mitochondrial membrane potential (MMP), cell cycle, and apoptosis were evaluated using flow cytometry and fluorescence microscopy. Ultrastructural changes and key protein expressions were analyzed via TEM, RT-qPCR, and immunoblotting. In vivo efficacy was validated using a T-ALL cell-line-derived xenograft (CDX) mouse model. Results: PZ2 exhibited superior cytotoxicity and an improved safety profile compared to inorganic arsenic trioxide (ATO). Transcriptomic data indicated strong enrichment in apoptosis and autophagy–lysosome pathways. PZ2 induced profound mitochondrial oxidative stress, leading to ROS accumulation, MMP loss, and subsequent activation of caspase-dependent apoptosis—effects that were completely rescued by ROS scavengers. Furthermore, PZ2 triggered G2/M phase arrest and activated autophagic flux (upregulated GABARAPL1 and LC3-II, degraded p62). Notably, pharmacological inhibition of autophagy rescued PZ2-induced apoptosis, revealing a pro-death autophagic mechanism. In vivo, PZ2 significantly suppressed tumor growth and prolonged survival without overt systemic toxicity. Conclusions: PZ2 exhibits potent anti-T-ALL activity that may involve a dual mechanism: ROS-dependent mitochondrial apoptosis and pro-death autophagy potentially associated with GABARAPL1. This novel organic arsenical may represent a promising and potentially safer alternative for leukemia therapy, and these findings suggest a potential interplay between oxidative stress and autophagic cell death.
- Open Access
- 8 September 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Fulminant extramedullary relapse of multiple myeloma with rare cardiac, vascular, and multivisceral involvement: A case report
Multiple myeloma (MM) is a plasma cell malignancy that typically follows a protracted clinical course. Extramedullary disease (EMD) represents an aggressive manifestation of MM with a relatively low incidence, traditionally involving the skin and soft tissues. While MM usually progresses indolently, fulminant disease progression characterized by extensive multivisceral and vascular infiltration is exceptionally rare and seldom documented in the medical literature. This case illustrates a 64-year-old woman who presented with left chest wall mass and pain and was diagnosed with high-risk IgG-λ-type MM (R-ISS Stage II), harboring 1q21 amplification and IGH/FGFR3 translocation. Following 12 cycles of VCD (bortezomib, cyclophosphamide, and dexamethasone) induction, she achieved partial remission and proceeded to maintenance therapy with bortezomib and ixazomib. Fifteen months post-diagnosis, the patient presented with a rapidly enlarging abdominal wall mass. 18F-FDG PET-CT revealed widespread hypermetabolic activity involving the heart, major blood vessels, liver, spleen, lungs, and multiple soft tissue sites, indicating extensive EMD. Bone marrow examination showed only 1% plasma cells, demonstrating a marked dissociation between systemic EMD and medullary involvement. Despite salvage therapy with carfilzomib, liposomal doxorubicin, and dexamethasone, the patient’s condition deteriorated rapidly. Compounded by severe hypoproteinemia, electrolyte disturbances, and respiratory infection, the disease followed a fulminant course, ultimately leading to the patient’s death. This case represents a catastrophic transition of genetically high-risk MM from initial medullary involvement to widespread multivisceral and cardiovascular infiltration upon relapse. It highlights a rare phenotype of relapsed/refractory MM where aggressive extramedullary proliferation occurs independently of bone marrow progression. Such patients face a dismal prognosis and present a formidable challenge for current salvage therapeutic strategies.
- 8 September 2026
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 17
Open AccessFulminant extramedullary relapse of multiple myeloma with rare cardiac, vascular, and multivisceral involvement: A case report
Multiple myeloma (MM) is a plasma cell malignancy that typically follows a protracted clinical course. Extramedullary disease (EMD) represents an aggressive manifestation of MM with a relatively low incidence, traditionally involving the skin and soft tissues. While MM usually progresses indolently, fulminant disease progression characterized by extensive multivisceral and vascular infiltration is exceptionally rare and seldom documented in the medical literature. This case illustrates a 64-year-old woman who presented with left chest wall mass and pain and was diagnosed with high-risk IgG-λ-type MM (R-ISS Stage II), harboring 1q21 amplification and IGH/FGFR3 translocation. Following 12 cycles of VCD (bortezomib, cyclophosphamide, and dexamethasone) induction, she achieved partial remission and proceeded to maintenance therapy with bortezomib and ixazomib. Fifteen months post-diagnosis, the patient presented with a rapidly enlarging abdominal wall mass. 18F-FDG PET-CT revealed widespread hypermetabolic activity involving the heart, major blood vessels, liver, spleen, lungs, and multiple soft tissue sites, indicating extensive EMD. Bone marrow examination showed only 1% plasma cells, demonstrating a marked dissociation between systemic EMD and medullary involvement. Despite salvage therapy with carfilzomib, liposomal doxorubicin, and dexamethasone, the patient’s condition deteriorated rapidly. Compounded by severe hypoproteinemia, electrolyte disturbances, and respiratory infection, the disease followed a fulminant course, ultimately leading to the patient’s death. This case represents a catastrophic transition of genetically high-risk MM from initial medullary involvement to widespread multivisceral and cardiovascular infiltration upon relapse. It highlights a rare phenotype of relapsed/refractory MM where aggressive extramedullary proliferation occurs independently of bone marrow progression. Such patients face a dismal prognosis and present a formidable challenge for current salvage therapeutic strategies.
- Open Access
- 1 September 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1934512
Case Report: Blastic plasmacytoid dendritic cell neoplasm mimicking systemic lymphoma: a multidisciplinary diagnostic challenge
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from plasmacytoid dendritic cell precursors. While classic cases present with prominent cutaneous nodules and lymphadenopathy, predominant generalized lymphadenopathy can obscure the diagnosis, frequently resulting in a misdiagnosis of systemic lymphoma. Case presentation: A 56-year-old male presented with a one-month history of generalized pruritic erythema and multi-regional lymphadenopathy. Initial PET-CT demonstrated systemic lymphadenopathy and splenomegaly with increased metabolic activity, mimicking lymphoma. To establish a definitive diagnosis, integrated biopsies of the skin, bone marrow, and inguinal lymph nodes were performed. Bone marrow cytology revealed that unidentified cells accounted for 7% of the total nucleated cells. Immunohistochemical analysis revealed neoplastic cells positive for CD123, CD4, CD56, TCF4, and TCL1, confirming the diagnosis of BPDCN. The patient achieved complete remission (CR) after two cycles of induction chemotherapy with the DA (daunorubicin and cytarabine) regimen, followed by successful consolidation via allogeneic hematopoietic stem cell transplantation (allo-HSCT). At the 4-month post-transplant follow-up, the patient remains in stable remission with no evidence of disease recurrence. Conclusion: This report details a BPDCN presentation that closely mimics systemic lymphoma. A definitive diagnosis hinges on the integration of multi-site histopathological analysis and comprehensive radiographic findings. Early diagnostic precision is paramount for the timely initiation of intensified therapeutic strategies, such as allo-HSCT, which remain the cornerstone for improving long-term survival in this recalcitrant malignancy.
- 1 September 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1934512
Open AccessCase Report: Blastic plasmacytoid dendritic cell neoplasm mimicking systemic lymphoma: a multidisciplinary diagnostic challenge
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from plasmacytoid dendritic cell precursors. While classic cases present with prominent cutaneous nodules and lymphadenopathy, predominant generalized lymphadenopathy can obscure the diagnosis, frequently resulting in a misdiagnosis of systemic lymphoma. Case presentation: A 56-year-old male presented with a one-month history of generalized pruritic erythema and multi-regional lymphadenopathy. Initial PET-CT demonstrated systemic lymphadenopathy and splenomegaly with increased metabolic activity, mimicking lymphoma. To establish a definitive diagnosis, integrated biopsies of the skin, bone marrow, and inguinal lymph nodes were performed. Bone marrow cytology revealed that unidentified cells accounted for 7% of the total nucleated cells. Immunohistochemical analysis revealed neoplastic cells positive for CD123, CD4, CD56, TCF4, and TCL1, confirming the diagnosis of BPDCN. The patient achieved complete remission (CR) after two cycles of induction chemotherapy with the DA (daunorubicin and cytarabine) regimen, followed by successful consolidation via allogeneic hematopoietic stem cell transplantation (allo-HSCT). At the 4-month post-transplant follow-up, the patient remains in stable remission with no evidence of disease recurrence. Conclusion: This report details a BPDCN presentation that closely mimics systemic lymphoma. A definitive diagnosis hinges on the integration of multi-site histopathological analysis and comprehensive radiographic findings. Early diagnostic precision is paramount for the timely initiation of intensified therapeutic strategies, such as allo-HSCT, which remain the cornerstone for improving long-term survival in this recalcitrant malignancy.
- Open Access
- 21 August 2026
- Published by Elsevier in Asian Journal of Surgery
Primary malignant peritoneal epithelioid perivascular epithelioid cell tumor in an elderly woman
- 21 August 2026
- Published by Elsevier in Asian Journal of Surgery
Open AccessPrimary malignant peritoneal epithelioid perivascular epithelioid cell tumor in an elderly woman
- Open Access
- 18 May 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Superior anti-DLBCL efficacy of novel organic arsenical Z2-A-Z2 through ROS-mediated apoptosis and critical NF-κB/IκBα signaling pathway inhibition
Objective: Diffuse large B-cell lymphoma (DLBCL) often resists therapy due to aberrant activation of NF-κB signaling pathway. We synthesized and evaluated Z2-A-Z2, a novel organic arsenical, hypothesized to target this survival pathway, aiming to assess its efficacy and mechanism against DLBCL. Materials and methods: The novel compound Z2-A-Z2 was synthesized and verified by 1 H CMR, 13 C CMR, and high-resolution mass spectrometry. Its anti-proliferative activity was assessed in GCB- and ABC-subtype DLBCL cell lines and normal peripheral blood mononuclear cells (PBMCs) using CCK-8 assays. Mechanisms were elucidated through flow cytometry (apoptosis, ROS, ΔΨm), Western blot (apoptotic and NF-κB pathway proteins), and enzyme activity assays. The causal role of ROS was confirmed by N-Acetylcysteine rescue (NAC) experiments, and the criticality of NF-κB inhibition was validated using p65 overexpression and pharmacological inhibition. Efficacy and safety were ultimately verified in SU-DHL-6 and U2932 xenograft model. Results: Z2-A-Z2 demonstrated potent and selective anti-proliferative activity against DLBCL cell lines, achieving an average IC₅₀ of approximately 1.1 µM. This efficacy was 3- to 6-fold superior to arsenic trioxide (ATO), while exhibiting minimal cytotoxicity toward normal PBMCs and B cells. Mechanistically, Z2-A-Z2 induced profound mitochondrial-mediated apoptosis and G2/M cell cycle arrest through a unique dual action of simultaneously triggering catastrophic oxidative stress and critically suppressing the pro-survival NF-κB/IκBα signaling axis. Further investigation revealed a bidirectional regulation where ROS acts upstream to suppress p65 activity, while p65 in turn modulates drug-induced ROS generation. In vivo studies further validated these findings, showing that Z2-A-Z2 resulted in a robust suppression of tumor growth in a xenograft model, accompanied by diminished NF-κB/IκBα activity and increased apoptosis, alongside an excellent safety profile. Conclusion: Z2-A-Z2 is a promising organic arsenical with superior efficacy and safety over ATO. Its unique dual-action strategy of simultaneously inducing oxidative stress and critically inhibiting the NF-κB/IκBα signaling axis, positioning it as a strong clinical candidate for effectively treating DLBCL.
- 18 May 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Open AccessSuperior anti-DLBCL efficacy of novel organic arsenical Z2-A-Z2 through ROS-mediated apoptosis and critical NF-κB/IκBα signaling pathway inhibition
Objective: Diffuse large B-cell lymphoma (DLBCL) often resists therapy due to aberrant activation of NF-κB signaling pathway. We synthesized and evaluated Z2-A-Z2, a novel organic arsenical, hypothesized to target this survival pathway, aiming to assess its efficacy and mechanism against DLBCL. Materials and methods: The novel compound Z2-A-Z2 was synthesized and verified by 1 H CMR, 13 C CMR, and high-resolution mass spectrometry. Its anti-proliferative activity was assessed in GCB- and ABC-subtype DLBCL cell lines and normal peripheral blood mononuclear cells (PBMCs) using CCK-8 assays. Mechanisms were elucidated through flow cytometry (apoptosis, ROS, ΔΨm), Western blot (apoptotic and NF-κB pathway proteins), and enzyme activity assays. The causal role of ROS was confirmed by N-Acetylcysteine rescue (NAC) experiments, and the criticality of NF-κB inhibition was validated using p65 overexpression and pharmacological inhibition. Efficacy and safety were ultimately verified in SU-DHL-6 and U2932 xenograft model. Results: Z2-A-Z2 demonstrated potent and selective anti-proliferative activity against DLBCL cell lines, achieving an average IC₅₀ of approximately 1.1 µM. This efficacy was 3- to 6-fold superior to arsenic trioxide (ATO), while exhibiting minimal cytotoxicity toward normal PBMCs and B cells. Mechanistically, Z2-A-Z2 induced profound mitochondrial-mediated apoptosis and G2/M cell cycle arrest through a unique dual action of simultaneously triggering catastrophic oxidative stress and critically suppressing the pro-survival NF-κB/IκBα signaling axis. Further investigation revealed a bidirectional regulation where ROS acts upstream to suppress p65 activity, while p65 in turn modulates drug-induced ROS generation. In vivo studies further validated these findings, showing that Z2-A-Z2 resulted in a robust suppression of tumor growth in a xenograft model, accompanied by diminished NF-κB/IκBα activity and increased apoptosis, alongside an excellent safety profile. Conclusion: Z2-A-Z2 is a promising organic arsenical with superior efficacy and safety over ATO. Its unique dual-action strategy of simultaneously inducing oxidative stress and critically inhibiting the NF-κB/IκBα signaling axis, positioning it as a strong clinical candidate for effectively treating DLBCL.
- Open Access
- 1 April 2026
- Published by Springer Nature in BMC Oral Health
- Vol. 26 (1)
Craniofacial extramedullary plasmacytoma with hard palate and bilateral cervical lymph node involvement: a diagnostic challenge and literature review
Extramedullary plasmacytoma (EMP) is a rare plasma cell tumor primarily affecting extramedullary sites without involving the bone marrow. While 80–90% of cases occur in the head and neck regions, craniofacial EMP involving the hard palate and spreading to bilateral cervical lymph nodes is exceptionally rare. A 59-year-old female presented with a one-year history of a nasal mass on the right anterior side. Her medical history showed basal cell carcinoma and oropharyngeal tumors. Physical examination revealed a mulberry-like mass in the right nasal vestibule. Computed tomography (CT) of the paranasal sinus revealed a space-occupying lesion in the nasal cavity. The patient underwent surgical resection, with histopathological and immunohistochemical analysis confirming plasmacytoma. Bone marrow aspiration and biopsy showed no significant abnormalities. Subsequent positron emission tomography-computed tomography (PET-CT) identified involvement of bilateral cervical lymph nodes and the hard palate. This was confirmed by CT-guided fine-needle aspiration biopsy, with pathological results consistent with those of the nasal lesion. The final diagnosis was EMP involving the hard palate and bilateral cervical lymph nodes. The patient underwent four cycles of chemotherapy using the VCD regimen (bortezomib, cyclophosphamide, dexamethasone), followed by localized radiotherapy (36 Gy in 18 fractions). Currently, she shows no evidence of systemic involvement and is recovering well. We report a rare case of primary sinonasal EMP with involvement of the hard palate and bilateral cervical lymph nodes. Due to its non-specific clinical features, sinonasal EMP is often misdiagnosed as other head and neck malignancies. Pathological biopsy is crucial for definitive diagnosis. Treatment should be individualized based on disease extent, including surgery, radiotherapy, and systemic therapies as appropriate. The online version contains supplementary material available at 10.1186/s12903-026-08235-4.
- 1 April 2026
- Published by Springer Nature in BMC Oral Health
- Vol. 26 (1)
Open AccessCraniofacial extramedullary plasmacytoma with hard palate and bilateral cervical lymph node involvement: a diagnostic challenge and literature review
Extramedullary plasmacytoma (EMP) is a rare plasma cell tumor primarily affecting extramedullary sites without involving the bone marrow. While 80–90% of cases occur in the head and neck regions, craniofacial EMP involving the hard palate and spreading to bilateral cervical lymph nodes is exceptionally rare. A 59-year-old female presented with a one-year history of a nasal mass on the right anterior side. Her medical history showed basal cell carcinoma and oropharyngeal tumors. Physical examination revealed a mulberry-like mass in the right nasal vestibule. Computed tomography (CT) of the paranasal sinus revealed a space-occupying lesion in the nasal cavity. The patient underwent surgical resection, with histopathological and immunohistochemical analysis confirming plasmacytoma. Bone marrow aspiration and biopsy showed no significant abnormalities. Subsequent positron emission tomography-computed tomography (PET-CT) identified involvement of bilateral cervical lymph nodes and the hard palate. This was confirmed by CT-guided fine-needle aspiration biopsy, with pathological results consistent with those of the nasal lesion. The final diagnosis was EMP involving the hard palate and bilateral cervical lymph nodes. The patient underwent four cycles of chemotherapy using the VCD regimen (bortezomib, cyclophosphamide, dexamethasone), followed by localized radiotherapy (36 Gy in 18 fractions). Currently, she shows no evidence of systemic involvement and is recovering well. We report a rare case of primary sinonasal EMP with involvement of the hard palate and bilateral cervical lymph nodes. Due to its non-specific clinical features, sinonasal EMP is often misdiagnosed as other head and neck malignancies. Pathological biopsy is crucial for definitive diagnosis. Treatment should be individualized based on disease extent, including surgery, radiotherapy, and systemic therapies as appropriate. The online version contains supplementary material available at 10.1186/s12903-026-08235-4.
- 9 March 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 174, 109734
Epigenetic reprogramming by organic arsenic CZ2 elicits potent antitumor responses in DLBCL through TMS1 restoration
- 9 March 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 174, 109734
Epigenetic reprogramming by organic arsenic CZ2 elicits potent antitumor responses in DLBCL through TMS1 restoration
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 22, 1-8
Dual Left Atrial Masses Causing Inflow Obstruction: A Rare Presentation of Primary Cardiac Intimal Sarcoma
Aim: Primary cardiac intimal sarcoma is a rare entity with a poor prognosis, often requiring distinction from other undifferentiated cardiac sarcomas. Case Presentation: A 55-year-old female presented with symptoms of heart failure. Imaging identified dual left atrial masses compromising mitral inflow and pulmonary venous return. Surgical excision was performed, and morphological analysis revealed a high-grade spindle cell sarcoma. Crucially, the diagnostic dilemma was resolved through molecular testing; immunohistochemistry showed diffuse overexpression of MDM2 and CDK4, and fluorescence in situ hybridization (FISH) confirmed the amplification of the MDM2 and CDK4 loci. Conclusion: This case illustrates the diagnostic utility of MDM2 and CDK4 as specific biomarkers for cardiac intimal sarcoma. It reinforces the necessity of a multidisciplinary approach involving advanced molecular pathology to ensure accurate classification and appropriate management of rare cardiac malignancies.
- 1 March 2026
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. ume 22, 1-8
Open AccessDual Left Atrial Masses Causing Inflow Obstruction: A Rare Presentation of Primary Cardiac Intimal Sarcoma
Aim: Primary cardiac intimal sarcoma is a rare entity with a poor prognosis, often requiring distinction from other undifferentiated cardiac sarcomas. Case Presentation: A 55-year-old female presented with symptoms of heart failure. Imaging identified dual left atrial masses compromising mitral inflow and pulmonary venous return. Surgical excision was performed, and morphological analysis revealed a high-grade spindle cell sarcoma. Crucially, the diagnostic dilemma was resolved through molecular testing; immunohistochemistry showed diffuse overexpression of MDM2 and CDK4, and fluorescence in situ hybridization (FISH) confirmed the amplification of the MDM2 and CDK4 loci. Conclusion: This case illustrates the diagnostic utility of MDM2 and CDK4 as specific biomarkers for cardiac intimal sarcoma. It reinforces the necessity of a multidisciplinary approach involving advanced molecular pathology to ensure accurate classification and appropriate management of rare cardiac malignancies.
- Top Cited PapersOpen Access
- 23 February 2026
- Published by American Chemical Society (ACS) in Chemical & Biomedical Imaging
- Vol. 4 (6) , 1018-1042
pH-Responsive Materials for Therapy and Precision Biomedical Imaging
The acidic tumor microenvironment (TME) presents a key pathological hallmark that can be exploited for targeted therapeutic and diagnostic interventions. This review systematically outlines the design and application of pH-responsive materials in biomedical imaging and therapy, emphasizing their role in achieving spatial and temporal control over drug delivery and imaging contrast. We first detail the fundamental chemical mechanisms underpinning pH responsiveness, including dynamic covalent bonds (e.g., acylhydrazone, imine, orthoester, and borate ester), metal–ligand coordination bonds, and pH-dependent noncovalent interactions. These principles are then translated into a variety of nanocarrier platforms, such as polymeric micelles, liposomes, hydrogels, metal–organic frameworks (MOFs), PROTAC conjugates, and self-assembling peptides, all of which are designed to undergo structural or functional changes in response to acidic conditions. The convergence of these smart materials with advanced imaging modalities has enabled transformative applications, including activatable probes for high-contrast functional imaging, multistimuli responsive theranostics, organelle-precision targeting, and spatiotemporally programmed release systems. These innovations collectively enhance diagnostic accuracy, therapeutic specificity, and the potential for real-time treatment monitoring. However, clinical translation remains challenged by issues related to reproducible synthesis, long-term biocompatibility, and the complex heterogeneity of in vivo environments. Future advancements are anticipated to focus on the integration of artificial intelligence for material design, the development of closed-loop feedback systems, and rigorous translational studies to bridge the gap between laboratory innovation and clinical application.
- 23 February 2026
- Published by American Chemical Society (ACS) in Chemical & Biomedical Imaging
- Vol. 4 (6) , 1018-1042
Top Cited PapersOpen AccesspH-Responsive Materials for Therapy and Precision Biomedical Imaging
The acidic tumor microenvironment (TME) presents a key pathological hallmark that can be exploited for targeted therapeutic and diagnostic interventions. This review systematically outlines the design and application of pH-responsive materials in biomedical imaging and therapy, emphasizing their role in achieving spatial and temporal control over drug delivery and imaging contrast. We first detail the fundamental chemical mechanisms underpinning pH responsiveness, including dynamic covalent bonds (e.g., acylhydrazone, imine, orthoester, and borate ester), metal–ligand coordination bonds, and pH-dependent noncovalent interactions. These principles are then translated into a variety of nanocarrier platforms, such as polymeric micelles, liposomes, hydrogels, metal–organic frameworks (MOFs), PROTAC conjugates, and self-assembling peptides, all of which are designed to undergo structural or functional changes in response to acidic conditions. The convergence of these smart materials with advanced imaging modalities has enabled transformative applications, including activatable probes for high-contrast functional imaging, multistimuli responsive theranostics, organelle-precision targeting, and spatiotemporally programmed release systems. These innovations collectively enhance diagnostic accuracy, therapeutic specificity, and the potential for real-time treatment monitoring. However, clinical translation remains challenged by issues related to reproducible synthesis, long-term biocompatibility, and the complex heterogeneity of in vivo environments. Future advancements are anticipated to focus on the integration of artificial intelligence for material design, the development of closed-loop feedback systems, and rigorous translational studies to bridge the gap between laboratory innovation and clinical application.